Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEISH-F3 vaccine for visceral leishmaniasis prevention
NCT02071758Phase 1Completed
- Sponsor
- Access to Advanced Health Institute
- Start
- Apr 2014
- Primary completion
- Dec 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LEISH-F3 + GLA-SE in visceral leishmaniasis (VL) (4 arms), sponsored by Access to Advanced Health Institute. Primary endpoint: Number of Adverse Events at 421 days. Started Apr 2014; status: completed.
02
Drugs
LEISH-F3 + GLA-SE
03
Conditions
visceral leishmaniasis (VL)
Beyond the preview
Go deeper on NCT02071758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02071758.